- A prospective cohort study finds that tamoxifen (vs no tamoxifen) treatment reduces the recurrence rate by 62% in men with breast cancer.
Why this matters
- These results are from the first prospective cohort study of the benefits of tamoxifen in men with breast cancer.
- Prospective multicenter cohort study of 448 men in the German national prospective cancer registry.
- DFS is defined as the interval between the date of diagnosis and locoregional recurrence, distant recurrence, or death (whichever occurs first).
- Funding: None.
- Median follow-up was 39 (range, 2-89) months.
- Most tumors were >20 mm.
- 43.5% of men had positive axillary lymph nodes.
- 98.4% of men had hormone receptor positivity.
- DFS in men not receiving tamoxifen was lower compared with those receiving tamoxifen (P=.002).
- Tamoxifen recipients had a lower rate of recurrence or death as a single category (13.9% vs 22.6%) compared with those not receiving tamoxifen.
- Tamoxifen reduced the recurrence rate by 62% (HR, 0.38; P=.008) after adjustment for numerous factors.
- The most frequent metastatic sites were the bone followed by locoregional sites, liver, lungs and/or pleura, distant lymph nodes, brain, and rectum.
- Observational design.